問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

Division of Thoracic Medicine

Division of Infectious Disease

National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

National Taiwan University Cancer Center

Division of General Internal Medicine

更新時間:2025-03-04

余忠仁Yu, Chong-Jen
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 9 個月

篩選

List

391Cases

2021-01-01 - 2025-06-30

Phase III

Active
A Phase 3, Randomized, Open-label, Multi-country Study to Evaluate the Immunogenicity, Safety, Reactogenicity and Persistence of a Single Dose of the RSVPreF3 OA Investigational Vaccine and Different Revaccination Schedules in Adults Aged 60 Years and Above
  • Condition/Disease

    Respiratory Syncytial Virus Infections

  • Test Drug

    RSVPreF3 OA investigational vaccine

Participate Sites
7Sites

Recruiting5Sites

Terminated2Sites

2016-07-01 - 2022-12-31

Others

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2005-11-01 - 2006-07-31

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2020-04-01 - 2028-12-31

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-12-01 - 2027-12-31

Phase II

Active
A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC)
  • Condition/Disease

    Non-Small Cell Lung Cancer (NSCLC)

  • Test Drug

    injection

Participate Sites
10Sites

Recruiting10Sites

2021-01-01 - 2024-12-31

Phase II

Completed
A Phase 2, Open-Label, Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
  • Condition/Disease

    subjects with KRASG12C mutant NSCLC

  • Test Drug

    RMC-4630 Sotorasib

Participate Sites
5Sites

Recruiting5Sites

2020-05-01 - 2024-04-15

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2023-12-08 - 2024-08-28

Phase I

Completed
A Phase Ib Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Patients With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Patients With Metastatic Colorectal Cancer
  • Condition/Disease

    Colorectal Cancer ;Non-Small Cell Lung Cancer

  • Test Drug

    GDC-1971CetuximabOsimertinib

Participate Sites
2Sites

Recruiting2Sites

2021-08-01 - 2024-11-01

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2015-11-30 - 2026-05-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites